Clinical trials
Lupus clinical trials
Below are recruiting lupus clinical trials, each written for real people, not researchers. We’re tracking 326 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06792799RecruitingEarly Phase 1
CAR-NK cells for B-cell autoimmune diseases
This early phase trial tests a new treatment made from immune cells (CAR-NK cells) that target and destroy overactive B cells. It may help people with lupus, certain kidney diseases, or nephrotic syndrome that hasn't responded to standard therapies.
Hangzhou, ZhejiangAges 3 years+ - NCT06249438RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06711146RecruitingEarly Phase 1
CAR T-cell therapy for active lupus
This study tests a new treatment using a type of immune cell therapy (CAR T-cells) for people with moderate to severe systemic lupus erythematosus (SLE) that has not responded well to standard treatments. The therapy aims to reset the immune system to reduce lupus activity.
Hangzhou, ZhejiangAges 18 years+ - NCT06659029Recruiting
Study on pregnancy outcomes in lupus patients using anifrolumab
This study tracks the health of pregnant women with moderate to severe lupus who have been treated with anifrolumab, compared to those treated with other lupus medications. It aims to understand how these treatments affect both mother and baby.
Wilmington, North CarolinaAges Any age - NCT06647069RecruitingPhase 1
Testing a new drug for lupus and rheumatoid arthritis
This study tests an investigational drug called SAR448501/DR-0201 in people with active lupus or rheumatoid arthritis who have not responded well to standard treatments. The goal is to see if the drug is safe and helps control disease activity.
Melbourne, VictoriaAges 18–75 - NCT06614270Recruiting
CAR-NK cell therapy for severe autoimmune diseases
This trial tests a new type of immune cell therapy using modified natural killer cells (CAR-NK) that target a protein called CD19 and produce helpful signals (IL-10 and IL-15). It is for people with certain autoimmune diseases that have not improved with standard treatments or have come back after getting better.
Hangzhou, ZhejiangAges 18–65 - NCT06594068RecruitingPhase 4
Anifrolumab in breastfeeding mothers with lupus
This study is looking at how the lupus medicine anifrolumab passes into breast milk and affects mothers and their babies. It is for women who are already taking anifrolumab for lupus and are breastfeeding a baby born at 32 weeks or later.
Las Vegas, NevadaAges 18–130 - NCT06599658RecruitingPhase 2
COVID-19 booster and flu vaccine timing for people with weak immune systems
This study tests the best timing for a COVID-19 booster and flu shot in people with weakened immune systems, such as organ transplant recipients, people living with HIV, or those with certain autoimmune conditions. It aims to help patients get better protection from both vaccines.
Montreal, QuebecAges 18 years+ - NCT06599411Recruiting
Skin biomarkers for inflammatory disease treatment
This study looks for clues in your skin and blood that could predict how well you'll respond to treatments for conditions like eczema, psoriasis, or lupus. It aims to help doctors choose the best therapy for you.
ParisAges 18 years+ - NCT06570798RecruitingPhase 2
Testing Two Drugs for Lupus and Rheumatoid Arthritis
This trial tests two study drugs, inebilizumab and blinatumomab, for people with lupus (SLE) or rheumatoid arthritis (RA) that hasn't gotten better with standard treatments. It focuses on those with active disease, especially lupus-related kidney problems.
Scottsdale, ArizonaAges 18–75 - NCT06557265RecruitingPhase 1/Phase 2
NKX019 for lupus kidney disease or membranous nephropathy
This trial tests an experimental cell therapy called NKX019 for people with active lupus nephritis (a type of kidney inflammation from lupus) or primary membranous nephropathy (another kidney condition) that hasn't gotten better after standard treatments. It may help if you have tried at least two treatments for lupus kidney disease or one for membranous nephropathy and still have active kidney disease.
Little Rock, ArkansasAges 18–75 - NCT06548607RecruitingEarly Phase 1
CAR-T therapy for autoimmune diseases
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
Bengbu, AnhuiAges 18–70 - NCT06527872Recruiting
Study of belimumab for lupus kidney disease in real life
This study looks at how well belimumab (Benlysta) works in real-world settings for adults with lupus nephritis (kidney inflammation caused by lupus). If you started belimumab in the past 6–24 months, the researchers will review your medical records to see how your kidney health has changed.
Baltimore, MarylandAges 18 years+ - NCT06465147RecruitingPhase 1
Cell therapy for hard-to-treat lupus (REACT-01)
This trial tests a new type of cell therapy (CAR T-cells) to see if it can stop the immune system from attacking the body in severe lupus. It’s for people ages 2–30 whose lupus is not controlled by other treatments and who are willing to be treated at Seattle Children’s Hospital.
Seattle, WashingtonAges 2–30 - NCT06426316Recruiting
Immune cells and migraines study
This study looks at how certain immune cells and inflammatory chemicals relate to migraines. If you have migraines or an autoimmune condition (like lupus, rheumatoid arthritis, or Crohn's disease), you may be able to participate. The goal is to understand what causes migraines.
Clermont-Ferrand, AURAAges 18–50 - NCT06435468Recruiting
Biocollection for rare childhood-onset immune diseases
This study collects blood and tissue samples from patients with rare immune system diseases that started in childhood, and from their relatives and healthy volunteers. The goal is to build a biocollection for future research to better understand these diseases.
Bron, BronAges 1 year+ - NCT06419205RecruitingPhase 2
ADX-097 for IgA nephropathy, lupus nephritis, or C3G
This study tests an experimental oral therapy called ADX-097 for people with three types of kidney disease: IgA nephropathy, lupus nephritis, or C3 glomerulopathy. The goal is to see if it’s safe and can help reduce kidney damage.
Hollywood, FloridaAges 16 years+ - NCT06347718RecruitingPhase 1/Phase 2
Car-T cells for autoimmune disease
This study tests a type of immunotherapy called CAR-T cells for people with certain autoimmune diseases like lupus, scleroderma, or myositis. It aims to see if this treatment can help when standard medicines haven't worked well enough.
Erlangen, BavariaAges 18 years+ - NCT06285279RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune kidney diseases
This trial tests a new type of cell therapy called CAR-T cells that target two proteins (BCMA and CD19) to treat autoimmune kidney diseases that are not responding to standard treatments. The goal is to see if this therapy can help control the disease and improve kidney function.
Nanjing, JiangsuAges 18–65 - NCT06217107Recruiting
Wellness and work support for lupus and lupus nephritis
This study tests a wellness and work support program for women with lupus or lupus nephritis. The goal is to help you manage your health and connect with others through an online program.
Atlanta, GeorgiaAges 18 years+ - NCT06208514Recruiting
Brief Pain Exposure Therapy for chronic pain conditions
This study tests a type of talk therapy called Brief Pain Exposure Therapy (BPET) for people with certain chronic pain conditions like fibromyalgia, lupus, or chronic low back pain. It aims to help reduce pain by changing how your brain responds to it.
Ann Arbor, MichiganAges 18 years+ - NCT06182969RecruitingPhase 1/Phase 2
APG-2575 for mild to moderate lupus
This trial tests an experimental drug called APG-2575 for people with mild to moderate lupus. It aims to see if the drug can help control lupus activity and improve symptoms.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06189157RecruitingPhase 1/Phase 2
Testing MB-CART19.1 therapy for severe lupus
This trial tests a new type of treatment called CAR T-cell therapy (MB-CART19.1) for people with severe lupus that has not responded to other treatments. It aims to see if this therapy can help control lupus and improve organ function.
ErlangenAges 18 years+ - NCT05029336RecruitingPhase 2
Stem cell transplant using your own cells for autoimmune disease
This Phase 2 study tests an autologous stem cell transplant (a treatment using your own blood-forming stem cells) for severe systemic sclerosis or severe lupus. The goal is to reset the immune system to help control the autoimmune disease.
Philadelphia, PennsylvaniaAges 8–25
Hear when a new Lupus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lupus?
- Yes. Clin2 currently lists 326 recruiting lupus studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.